Submission Deadline
10 Mar 2024 (Vol 47 , Iss 03 )

Upcoming Publication
31 Mar 2024 (Vol 47 , Iss 03 )

Archive-

Teikyo Medical Journal


Journal ID : TMJ-14-02-2024-11595
Total View : 395

Title : Mode of delivery-based estimate of the mother to fetus vertical infection of HCV: A multicenter observational study.

Abstract :

HCV is the primary cause of chronic viral hepatitis, and it is estimated that one-third of those infected will develop liver cancer. Mother-to-infant transmission may become the primary route of HCV infection in the future, as there is no current method to prevent vertical transmission. The study included 400 pregnant women and their neonates, with 98 infants born to 98 HCV-positive mothers, resulting in a 100% vertical transmission rate for HCV-NS4 antigen. The mode of delivery did not affect the transmission rate of HCV-NS4 antigen, with 64 cases (22.9%) of vaginal delivery and 34 cases (28.3%) of cesarean section. The transmission rate of HCV antigen did not differ significantly between children born via vaginal delivery or cesarean section after membrane rupture.

Full article
Journal ID : TMJ-10-02-2024-11594
Total View : 379

Title : Implication Of Isolated Anti-Hbc Antibodies Among Mauritanian Blood Donors

Abstract :

Blood transfusion safety is an important health issue particularly in regions endemic to hepatitis B virus (HBV) infection. In this research, our goal was to investigate the prevalence of isolated HBV core antibodies (IAHBc) in Mauritanian blood donors and the risk of hepatitis B reactivation associated with this serological pattern. Samples of HBV surface antigen (HBsAg)-negative blood donors were collected from the National Center of Blood Transfusion in Nouakchott and screened for both hepatitis B core antibodies (anti-HBc) and hepatitis B surface antibodies (anti-HBs) using Mini VIDAS. Plasma HBV DNA was determined using a quantitative real-time polymerase chain reaction in subjects with isolated anti-HBc (IAHBc). Out of the 320 healthy donors recruited for this study, 48.7% (156/320) had anti-HBc and 14.7% (47/320) were IAHBc carriers. No HBV DNA was detected in any of the subjects. In the first evaluation of blood safety in the country, no occult HBV infection was detected. Nevertheless, screening for IAHBc and anti-HBc antibodies should be introduced, considering the risk associated with these antibodies and their relatively high prevalence in our cohort.

Full article

Journal Visit

Top Visit

Medium Visit

Less Visit

Not Visit

//